4-(2-(6-cyanoquinazolin-4-ylamino)ethyl)-N-(2-methoxyethyl)benzamide

ID: ALA4866990

PubChem CID: 71679328

Max Phase: Preclinical

Molecular Formula: C21H21N5O2

Molecular Weight: 375.43

Molecule Type: Unknown

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  COCCNC(=O)c1ccc(CCNc2ncnc3ccc(C#N)cc23)cc1

Standard InChI:  InChI=1S/C21H21N5O2/c1-28-11-10-24-21(27)17-5-2-15(3-6-17)8-9-23-20-18-12-16(13-22)4-7-19(18)25-14-26-20/h2-7,12,14H,8-11H2,1H3,(H,24,27)(H,23,25,26)

Standard InChI Key:  DJDSVNGBIWOUMP-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 28 30  0  0  0  0  0  0  0  0999 V2000
    4.6458   -7.6147    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6447   -8.4342    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3527   -8.8432    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3510   -7.2058    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0596   -7.6111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0584   -8.4317    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7646   -8.8408    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.4765   -8.4337    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4776   -7.6131    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.7669   -7.1995    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9386   -7.2068    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2308   -6.7983    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.7669   -6.3823    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.4747   -5.9737    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4747   -5.1565    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1824   -4.7480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8871   -5.1606    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5943   -4.7527    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5948   -3.9346    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8821   -3.5262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1778   -3.9364    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.3023   -3.5223    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.0106   -3.9299    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.3012   -2.7051    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.7177   -3.5204    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.4260   -3.9281    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.1331   -3.5186    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   13.8414   -3.9262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  6  2  0
  5  4  2  0
  4  1  1  0
  5  6  1  0
  5 10  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 11 12  3  0
  1 11  1  0
 10 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 16  1  0
 22 23  1  0
 22 24  2  0
 19 22  1  0
 23 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
M  END

Associated Targets(Human)

CDK1 Tchem Cyclin-dependent kinase 1 (3927 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 375.43Molecular Weight (Monoisotopic): 375.1695AlogP: 2.53#Rotatable Bonds: 8
Polar Surface Area: 99.93Molecular Species: NEUTRALHBA: 6HBD: 2
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 4.62CX LogP: 2.39CX LogD: 2.39
Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.59Np Likeness Score: -1.53

References

1.  (2019)  Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer, 

Source